drugset / Trial / NCT04473859

Study to Evaluate the Safety of FSR Peptide Versus Placebo Following Punch Biopsy

NCT04473859 ↗

Phase 1 Completed 49 enrolled Xequel Bio, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purposes of this study is to test the safety of the study drug (FSR peptide) after a punch biopsy in healthy subjects.

Timeline

Start
2008-03-06
Primary completion
2009-04-28
Completion
2009-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject FSR Peptide Peptide 20 unknown Topical
Subject FSR Peptide Peptide 50 unknown Topical
Subject FSR Peptide Peptide 100 unknown Topical
Subject FSR Peptide Peptide 200 unknown Topical

Indications

No indication recorded.